Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score) for Interventional Treatment in NSTE-ACS Patients: A Retrospective Cohort Analysis from a Single Center Involving 348 Individuals - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score) for Interventional Treatment in NSTE-ACS Patients: A Retrospective Cohort Analysis from a Single Center Involving 348 Individuals

  • By

  • Qichang Zhu

  • Yuan Zhang

  • Jiaxin Liu

  • Xin Wang

  • Jiayu Meng

  • Hongwei Tian

  • January 8, 2026

Share

Clinical Scorecard: Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score) for Interventional Treatment in NSTE-ACS Patients: A Retrospective Cohort Analysis from a Single Center Involving 348 Individuals

At a Glance

CategoryDetail
ConditionNon-ST-Elevation Acute Coronary Syndrome (NSTE-ACS)
Key MechanismsAssessment of risk factors, complexity of coronary artery lesions, hemodynamics, and ventricular dysfunction.
Target PopulationPatients with complex high-risk coronary heart disease, particularly those undergoing PCI.
Care SettingCardiology department in a hospital setting.

Key Highlights

  • CHIP Score integrates patient, procedural, and vascular factors for risk assessment.
  • Study involved 348 NSTE-ACS patients with a follow-up period of 36 months.
  • Primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE).
  • CHIP Score demonstrated predictive efficacy for MACCE in the studied population.
  • Study highlights the need for effective revascularization in high-risk patients.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of NSTE-ACS adheres to the Fourth Universal Definition of Myocardial Infarction.

Management

  • Utilization of CHIP Score for stratifying risk in patients undergoing PCI.

Monitoring & Follow-up

  • Follow-up through outpatient visits, medical records review, and telephone communication.

Risks

  • Identification of independent risk factors for adverse events in CHIP patients.

Patient & Prescribing Data

348 NSTE-ACS patients with complex coronary heart disease.

Effective revascularization is critical for improving quality of life and reducing cardiovascular event risk.

Clinical Best Practices

  • Employ CHIP Score for risk stratification in high-risk coronary heart disease patients.
  • Monitor patients closely for MACCE during follow-up periods.

Related Resources & Content

Original Source(s)

Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score) for Interventional Treatment in NSTE-ACS Patients: A Retrospective Cohort Analysis from a Single Center Involving 348 Individuals

  • by Qichang Zhu, Yuan Zhang, Jiaxin Liu, Xin Wang, Jiayu Meng, Hongwei Tian

  • January 8, 2026

Related Content

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

AI Outperforms MDs on Reasoning Tasks

Across six experiments—including a blinded, real-world ER evaluation—an OpenAI large language model outperformed physician baselines on multiple clinical reasoning tasks, though not on key safety endpoints such as cannot-miss diagnoses

Potential Role of IL-6 and IL-17 as Biomarkers in Early-Onset Coronary Artery Disease: A Cross-Sectional Analysis